Skip to content


Company Overview

Bionomics (NASDAQ:BNOX, ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing proprietary, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”).

Bionomics has a strategic partnership with Merck & Co., Inc with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Bionomics is currently based in Australia and the US and listed on the Australian Securities Exchange (ASX) under the ticker “BNO“, and trades in the US on NASDAQ Global Market (NASDAQ) under the ticker “BNOX” and OTCQX market under the ticker “BNOEF“.

NASDAQ Share Price

ASX Share Price



View ASX Announcements


Latest Presentations


Share Price Information


Share Ownership


For any queries relating to Bionomics shares (e.g. updating contact or ownership details, dividend payments etc) please contact:

Computershare Investor Services Pty Ltd
Level 5, 115 Grenfell Street
Adelaide, SA 5000
Telephone: (08) 8236 2300
Facsimile: (08) 8236 2305